ViroPharma To Host Analyst And Investor Seminar On September 21, 2012Sacramento BeeHypersensitivity to the active substance of Plenadren or to any of the excipients may occur. During acute adrenal insufficiency, parenteral administration of hydrocortis…

Telegraph.co.ukEverolimus for Advanced Breast Cancer: An Update From the BOLERO-2 TrialCancer NetworkAt the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium last week, Hope Rugo, MD, director of breast oncology and clinical trials e…

TCTMDKorean Registry Confirms Edge of Everolimus- Over Zotarolimus-Eluting StentsTCTMDAmong next-generation drug-eluting stents (DES), those that elute everolimus are more effective at reducing stent thrombosis and target lesion revascularization (TLR)…

Afinitor Helps Breast Tx in Older PatientsMedPage TodaySAN FRANCISCO — Older patients with advanced, relapsed, estrogen receptor-positive breast cancer had significant improvement in progression-free survival with no increased toxicity when the mTOR i…

Daily MailEverolimus: an alternative to chemotherapy?Telegraph.co.uk (blog)The drug was called Everolimus and, today, it received its formal welcome from Professor Stephen Johnston, Professor of Breast Medicine at The Royal Marsden. He said: "Ever…

ViroPharma To Host Analyst And Investor Seminar On September 21, 2012Equities.comHypersensitivity to the active substance of Plenadren or to any of the excipients may occur. During acute adrenal insufficiency, parenteral administration of hydrocortison…

VIROPHARMA INC : ViroPharma To Host Analyst And Investor Seminar On …4-tradersHypersensitivity to the active substance of Plenadren or to any of the excipients may occur. During acute adrenal insufficiency, parenteral administration of hydrocortisone…

Telegraph.co.ukBreast cancer drug everolimus 'biggest advance in years'Telegraph.co.ukUp to 8,000 women a year could benefit from everolimus, say specialists, after a trial indicated it could "stall" advanced cancer for about four mon…

The SunWonder drug can halt breast cancerThe SunTests showed Everolimus — also called Afinitor — lengthens life expectancy from four months to a year for patients who are ER positive, the most common form of advanced breast cancer. Dr Rachel Greig,…

Opposing ViewsAnthera prepares for late-stage lupus drug trialsBusinessweekThe company plans to run two 52-week trials that compare blisibimod to placebo in patients who have systemic lupus and whose symptoms are not fully controlled despite treatment …